Regulatory Approval Granted for Reformulated Ranitidine - Video

The U.S. FDA has approved reformulated ranitidine tablets, marking the reintroduction of this widely used H2 receptor antagonist following extensive regulatory review and updated safety assessments, alongside its continued inclusion in the WHO Essential Medicines List. This video highlights key global regulatory developments, including approvals in other regions, the continued inclusion of ranitidine in the WHO Essential Medicines List, and its ongoing clinical relevance in the management of acid-related disorders such as GERD and peptic ulcer disease.